Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02126670 · ClinicalTrials.gov registry record · Phase 2
ACT01 in Combination With Comp01-04 in Patients With Actinic Keratosis
A Phase 2 study, sponsored by Promius Pharma.
- Completed
- Registry status
- Phase 2
- Development phase
- 100
- Enrollment target
NCT02126670 is a Phase 2 study that has completed, run by Promius Pharma. The registered enrollment target is 100 participants.
The verdict
NCT02126670, a Phase 2 study, has completed, sponsored by Promius Pharma.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 100 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether or not ACT01 is effective and tolerable alone or when used in combination with Comp01, Comp02, Comp03 or Comp04 in patients with facial and/or scalp keratosis.
Interventions
- DRUG ACT01
- DRUG Comp01
- DRUG Comp02
- DRUG Comp03
- DRUG Comp04
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2014-04 |
| Est. Completion | 2014-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02126670
The ClinicalTrials.gov registry entry for NCT02126670 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Promius Pharma, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which ACT01 is the first listed.
NCT02126670 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02126670 about?
NCT02126670 is a clinical study titled "ACT01 in Combination With Comp01-04 in Patients With Actinic Keratosis". The purpose of this study is to determine whether or not ACT01 is effective and tolerable alone or when used in combination with Comp01, Comp02, Comp03 or Comp04 in patients with facial and/or scalp keratosis.
What is the current status of trial NCT02126670?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 100 participants. The study started on 2014-04. Estimated completion is 2014-09.
What interventions are being tested in trial NCT02126670?
The interventions under investigation include: ACT01 (DRUG), Comp01 (DRUG), Comp02 (DRUG), Comp03 (DRUG), Comp04 (DRUG).
Who is sponsoring clinical trial NCT02126670?
This trial is sponsored by Promius Pharma, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.